Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial

Abstract

Risedronate 5 mg prevents bone loss in early postmenopausal women, is well tolerated, and represents an effective choice to maintain bone mass and prevent osteoporosis.